Protara Therapeutics (NASDAQ:TARA – Get Free Report) and Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...

ATLANTA — Longtime 95.5 WSB radio host Scott Slade has announced he has been diagnosed with multiple myeloma, a type of blood ...

Patients who did not complete a distress screener were also less likely to receive autologous stem cell transplants.

The study evaluated 14 patients that were treated with cultivated autologous limbal epithelial cells (CALEC) and followed ...

Avantax Advisory Services Inc. boosted its position in Vericel Co. (NASDAQ:VCEL – Free Report) by 1.7% during the 4th quarter ...

CERo’s technology works by grafting onto patients’ own T-cells a receptor that binds to a naturally occurring human antigen ...

The study was led by Harvard Medical School and Massachusetts Eye and Ear researchers and surgeons. The researchers reported ...

The global autologous cell therapy market, valued at USD 10.12 billion in 2024, is poised for remarkable expansion, reaching a projected valuation of USD 44.55 billion by 2033. This growth, driven by ...